Anti-EGFR monoclonal antibody and electrolyte disorders
HUANG Letian
Abstract：Currently, the monoclonal antibody against epidermal growth factor receptor (EGFR) is of great significance for the treatment of multiple solid tumors.But such drugs can cause electrolyte disorders such as hypomagnesemia, hypocalcemia and hypokalemia.The early symptoms can be easily overlooked.With EGFR expressed in the distal convoluted tubules and collecting duct, the monoclonal antibodies inhibit the ions reabsorption in the renal medullary loop ascending branch, so that the excretion of magnesium ions in the urine increase.Hypocalcemia and hypokalemia occur subsequently.Different target drugs and different tumors have different incidence.The risk of hypomagnesemia is associated with treatment duration, patient age, and basal serum magnesium values.Patients who develop hypomagnesemia are more likely to have better prognosis.The treatment interval need to be extended when Grade 3 or 4 hypomagnesemia happen, while received intravenous electrolyte replacement.It is usually reversible.Using the previous clinical trials and studies, we discuss the incidence, mechanisms, risk factors, treatment and prognosis of electrolyte disorders induced by anti-EGFR targeted agents.
Keywords：Epithelial growth factor receptorMono clonal antibodiesElectrolyte disordersHypomagnesaemia
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 630-633 )